Pascal Brière – President, Biogaran, France
Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to…
Address: 15 bd Charles de Gaulle 92707 Colombes ,France
Tel: +33 (0)1 55 72 41 00
Biogaran, is an independent French laboratory focused on generic drugs and was born in 1996 at the initiative of the first independent French pharmaceutical group: Servier.
Today the group is second on the French market and produces 55% of its products within the country. The laboratory Biogaran has commissioned the Social Security savings of around € 1 billion since its inception in 1996.
The group distributes a wide variety of pharmaceutical medications through French pharmacies
Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to…
Biogaran was an initiative from Servier in the mid 1990s before there was even a generic pharmaceutical market in France. Could you speak of your history and of the origins…
Iconic French skincare specialist, Pierre Fabre has been enjoying a hot streak of late, with its dermo-cosmetics business registering hefty sales growth of more than EUR 350 (USD 392) million…
Christopher Cuniasse, managing director of Fagron France, sheds light on the specialty area of pharmaceutical compounding and its link with personalized medicine, noting the benefits it can deliver to health…
Éric Ducournau, global CEO of Pierre Fabre Group, the second largest dermo-cosmetic company worldwide and the third-largest French pharmaceutical laboratory, provides insights into the group’s on-going internationalization and its emerging…
Inventiva is a French clinical-stage biotech company focused on developing oral small molecule epigenetic modulators in therapeutic areas with high unmet medical needs such as fibrosis, lysosomal storage disorders and…
Inotrem is a French biotech company developing a novel approach to target inflammatory diseases based on the TREM-1 pathway. Its CEO, Dr Jean-Jacques Garaud explains why he decided to leave…
Anne-Laurence Sabatini, vice president of Cluster France, Canada & Benelux at LEO Pharma, discusses the transformation of the company and how this has trickled down to her cluster. Furthermore, she…
Phillipe Archinard CEO of Transgene shares insights on the latest technologies being developed by the gene therapy specialist, explains how France’s innovation landscape is improving, and highlights the current opportunities…
Olivier Laureau, global president of Servier Group, outlines the impact of recent acquisitions, the significance of Servier’s recently-opened commercial subsidiary in the US, the ongoing importance of France to the…
Stéphane Regnault, president of Vygon, shares how the company has grown in size and international footprint over the past several years as a leading domestic French medtech. Regnault goes on…
Brigitte Calles, newly appointed general manager of Ferring France discusses the important role the affiliate plays as a market leader in reproductive medicine & women’s health, gastroenterology and uro-oncology and…
Nicolas Chandellier, general manager of BD France, discusses the company’s historic positioning in France and how the organization has transformed to further act as a partner to the healthcare system…
Franck Cousserans, general manager of France and Belgium at Jazz Pharmaceuticals, highlights the company’s key products and the challenges of market access in France. Furthermore, he indicates the steps needed…
See our Cookie Privacy Policy Here
